Lung Cancer
Combination of Osimertinib and Chemotherapy Enhances Brain Control in Advanced EGFR-Mutated Lung Cancer: Results from FLAURA2 Trial
ESMO: LBA68 EGFR mutations are found in 10%-15% of non-small cell lung cancer (NSCLC) cases among European and Caucasian populations. ...
Delfi Diagnostics introduces a simple blood test to detect lung cancer early and accurately
Delfi Diagnostics is introducing its inaugural liquid biopsy test, fulfilling the long-standing vision of offering a groundbreaking blood-based screening tool ...
Tagrisso-chemo combo delays EGFR NSCLC progression by 9 months in first-line (IASLC WCLC 2023 Conference)
Against the formidable challenge of non-small cell lung cancer (NSCLC), AstraZeneca’s Tagrisso (osimertinib), when partnered with chemotherapy, has unveiled remarkable ...
New drug Enhertu shows promise for HER2-mutant lung cancer patients (IASLC WCLC 2023 Conference)
The International Association for the Study of Lung Cancer (IASLC) presented pivotal results from the DESTINY-Lung02 Phase II trial at ...
Roche’s Alecensa beats chemo in early-stage lung cancer, following Tecentriq’s lead
With Tecentriq approval, Roche is once again celebrating success, this time in a promising early-stage lung cancer trial starring Alecensa, ...
Tecentriq SC: A Swift Leap Forward in Cancer Treatment Receives Green Light
Roche has proudly unveiled that Tecentriq SC (atezolizumab) has received the stamp of approval from the Medicines and Healthcare products ...
Roche Unveils Interim TIGIT Overall Survival Data Following Unintended Release, Triggering Surge in Stocks
An unexpected revelation has provided the world with a sneak peek into Roche’s highly anticipated TIGIT data. Roche, which had ...
Lilly’s Retevmo Outperforms Gavreto in Lung Cancer Study
Source – Eli Lilly In the ongoing rivalry between Eli Lilly and Blueprint Medicines over their RET inhibitors, Eli Lilly ...
J&J’s Rybrevant Wins in Rare Lung Cancer; Awaits Tagrisso Showdown
Source – Johnson & Johnson In 2021, Johnson & Johnson’s Rybrevant received accelerated approval from the FDA, becoming the first ...
Insufficient use of gene sequencing for lung cancer in Europe
A recent report highlights that while next-generation sequencing (NGS) has the potential to improve patient outcomes and save money for ...
Lung Cancer Stage 3 Survival Rate: Everything You Need to Know
A Comprehensive Guide to Lung Cancer Stage 3 Survival Rate and Treatment Options This blog will reveal all about lung ...
